GoldenGolden
Genapsys

Genapsys

Genapsys is a company developing DNA sequencing technologies and systems founded in 2010 by Hesaam Esfandyarpour.

GenapSys aims to democratize access to Next-Generation Sequencing in order to advance genomics discovery, biomedical research, healthcare, diagnostics, agriculture and other fields.

GenapSys’s priority is to help researchers and clinicians have access to accurate and affordable sequencing at a point closer to patients in order to better treat cancer patients and also fight pandemic outbreaks such as COVID-19 caused by SARS-CoV-2. Other areas with applications to sequencing include food science, personalized medicine and forensics.

GenapSys announced in February, 2020, the launch of its gene sequencer in the Asia Pacific region of Korea, Singapore, Japan and China, in the midst of the Coronavirus outbreak. The company has expanded with 25 distributorship deals and $75 million in financing to scale its global presence. Sequencing is used to study strains and gene mutations in infected individuals to better understand the origin of the virus and containment strategies.

Timeline

February 6, 2020
Genapsys raises a $75,000,000 venture round from Oxford Finance.
November 2019
Genapsys raises a $90,000,000 series C round from Foresite Capital.
January 15, 2018
Genapsys raises a $32,500,000 series C round.
November 14, 2013
Genapsys raises a $37,000,000 series B round from Decheng Capital, IPV Capital and Yuri Milner.
March 22, 2013
Genapsys raises a $8,500,000 series A round.
October 24, 2012
Genapsys was founded by Hesaam Esfandyarpour.
September 1, 2012
Genapsys raises a $5,500,000 grant.

Funding rounds

People

Name
Role
LinkedIn

Alexia Perineau

Employee

Amin Mousavi

Employee

Andie Summers

Employee

Chandeep Khamba

Employee

Curt Becker

Employee

Davian Contreras

Employee

Derek Kan

Employee

Dhrumit Sheth

Employee

Gagan Gautam

Employee

Hadayat Seddiqi

Employee

Hassan Sazmand

Employee

Howard Goldstein

Employee

Ibrahim Hamisu

Employee

Kate Ho

Employee

Leila Rastegar Zegna

Advisor

Mark Eremeev

Employee

Mark Pratt

Employee

Nitin Kishore Gupta

Employee

nupur kohli

Employee

Rodrigo Teixeira

Employee

Rubal Sekhon

Employee

Saeid Vatannia

Employee

Sambit Basu

Employee

Sang Nguyen

Employee

Senthil Perumal

Employee

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
GenapSys
June 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- GenapSys, Inc. (GenapSys), a company developing a highly accurate and scalable electronic sequencing platform, today announced the appointment...
GenapSys
May 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- GenapSys, Inc. (GenapSys), ein Unternehmen, das eine hochpräzise und skalierbare elektronische Sequencing-Plattform entwickelt, gab heute...
GenapSys
May 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- GenapSys, Inc. (GenapSys), une société qui développe une plateforme de séquençage électronique hautement précise et évolutive, a annoncé...
FinSMEs
May 27, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Andrea Park
May 27, 2021
FierceBiotech
The series D will support further development of GenapSys' sequencing technology, which aims to offer a less expensive, more accessible alternative to other next-generation sequencing platforms.
May 27, 2021
BioSpace
GenapSys Announces $70 Million in Series D Equity Financing and Expansion of its Board of Directors - read this article along with other careers information, tips and advice on BioSpace
GenapSys
May 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- GenapSys, Inc. (GenapSys), a company developing a highly accurate and scalable electronic sequencing platform, today announced it has raised...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.